NASDAQ
CYCN

Cyclerion Therapeutics Inc

PHARMACEUTICAL PREPARATIONS
LIFE SCIENCES

Prices are adjusted according to historical splits.

Cyclerion Therapeutics Inc Stock Price

Vitals

Today's Low:
$0.5346
Today's High:
$0.5700
Open Price:
$0.5700
52W Low:
$0.35
52W High:
$3.05
Prev. Close:
$0.5647
Volume:
43092

Company Statistics

Market Cap.:
$0.024 billion
Book Value:
0.583
Revenue TTM:
$0.002 billion
Operating Margin TTM:
-2743%
Gross Profit TTM:
$-0.030 billion
Gross Profit TTM:
$-0.030 billion
Profit Margin:
0%
Return on Assets TTM:
-58.6%
Return on Equity TTM:
-106.9%

Company Profile

Cyclerion Therapeutics Inc had its IPO on 2019-04-02 under the ticker symbol CYCN.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. Cyclerion Therapeutics Inc has a staff strength of 0 employees.

Stock update

Shares of Cyclerion Therapeutics Inc opened at $0.57 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $0.53 - $0.57, and closed at $0.56.

This is a -1.03% slip from the previous day's closing price.

A total volume of 43,092 shares were traded at the close of the day’s session.

In the last one week, shares of Cyclerion Therapeutics Inc have increased by 0%.

Cyclerion Therapeutics Inc's Key Ratios

Cyclerion Therapeutics Inc has a market cap of $0.024 billion, indicating a price to book ratio of 0.988 and a price to sales ratio of 12.81.

In the last 12-months Cyclerion Therapeutics Inc’s revenue was $0.002 billion with a gross profit of $-0.030 billion and an EBITDA of $-0.052 billion. The EBITDA ratio measures Cyclerion Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Cyclerion Therapeutics Inc’s operating margin was -2743% while its return on assets stood at -58.6% with a return of equity of -106.9%.

In Q2, Cyclerion Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 89.8%.

Cyclerion Therapeutics Inc’s PE and PEG Ratio

Forward PE
-
Trailing PE
-
PEG
None

Its diluted EPS in the last 12-months stands at $-1.235 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cyclerion Therapeutics Inc’s profitability.

Cyclerion Therapeutics Inc stock is trading at a EV to sales ratio of 0.517 and a EV to EBITDA ratio of 0.587. Its price to sales ratio in the trailing 12-months stood at 12.81.

Cyclerion Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Cyclerion Therapeutics Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Cyclerion Therapeutics Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Cyclerion Therapeutics Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Cyclerion Therapeutics Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Cyclerion Therapeutics Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$0.56
52-Week High
$3.05
52-Week Low
$0.35
Analyst Target Price
$9

Cyclerion Therapeutics Inc stock is currently trading at $0.56 per share. It touched a 52-week high of $3.05 and a 52-week low of $3.05. Analysts tracking the stock have a 12-month average target price of $9.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Cyclerion Therapeutics Inc

The stock symbol (also called stock or share ticker) of Cyclerion Therapeutics Inc is CYCN

The IPO of Cyclerion Therapeutics Inc took place on 2019-04-02

Similar Industry Stocks (PHARMACEUTICAL PREPARATIONS)

Last Price
Chg
Chg%
$0.83
0.03
+3.75%
$3.4
0.06
+1.8%
$50.5
1.63
+3.34%
$0.13
-0
-2.26%
$6.37
-0.14
-2.15%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of drugs for serious diseases of the central nervous system (CNS). The company is headquartered in Cambridge, Massachusetts.

Address

301 BINNEY STREET, CAMBRIDGE, MA, US